Trials / Completed
CompletedNCT03015129
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer. Radiologic tumor assessment will be repeated every 8 weeks +/- 7 days for the first 48 weeks and then every 12 weeks +/- 7 days until PD. For patients who remain progression free 2 years post completion of protocol directed treatment, every 6 months +/- 1 month. irRECIST assessments will only be completed for patients continuing treatment beyond PD.
Conditions
- Endometrial Cancer
- Endometrial Carcinosarcoma
- Endometrial Carcinoma
- Endometrial Cancer Recurrent
- Endometrial Carcinoma, Recurrent
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | |
| DRUG | Tremelimumab |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
- First posted
- 2017-01-09
- Last updated
- 2024-02-06
- Results posted
- 2024-02-06
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03015129. Inclusion in this directory is not an endorsement.